Polly Clayden, HIV i-Base

The Medicines Control Council (MCC) of South Africa issued a press release on 12 September announcing that in view of additional data brought to their attention since the decision to deregister nevirapine for use in combating mother to child transmission, the time period for Boehringer Ingelheim to submit new evidence had been extended. It explains that new data must be submitted on the use of nevirapine in combination with other antiretrovirals for use for this indication.

The press release also says: “Appropriate treatment of the mother and the newborn child is also imperative, and the MCC urges healthcare professionals to use available interventions to improve the survival and health status of both mother and child.”

Ref: MCC Press Release, 12 September 2003